HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: An immunohistochemical and array comparative genomic hybridization study

Histopathology

Volumn 51, Issue 5, 2007, Pages 666-673

  Nowee, M E ^a   Dorsman, J C ^a   Piek, J M J ^a   Kosma, V M ^b,c   Hamalainen K ^b,c   Verheijen, R H M ^a   Van Diest, P J ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Array comparative genomic hybridization; Carcinogenesis; Fallopian tube carcinoma; HER 2 neu; Immunohistochemistry; Ovarian carcinoma; p27Kip1; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; CDKN1B PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COMPARATIVE GENOMIC HYBRIDIZATION; DNA DETERMINATION; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE TUBE CARCINOMA; CARCINOMA; CELL DIFFERENTIATION; DISEASE COURSE; DNA MICROARRAY; GENETICS; GENOMICS; METABOLISM; METHODOLOGY; PATHOLOGY; UTERINE TUBE TUMOR;

CARCINOMA; CELL DIFFERENTIATION; DISEASE PROGRESSION; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 35348884848     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02850.x     Document Type: Article

References (53)

1. Woolas R, Jacobs I, Davies AP et al. What is the true incidence of primary fallopian tube carcinoma? Int. J. Gynecol. Cancer 1994 4 384 388.
2. Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol. 2000 76 45 50.
3. Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary fallopian tube carcinoma. Obstet. Gynecol. Surv. 2005 60 247 252.
4. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003 97 389 404.
5. Lacy MQ, Hartmann LC, Keeney GL et al. c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer 1995 75 2891 2896.
6. Zheng W, Sung CJ, Cao P et al. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol. Oncol. 1997 64 38 48.
7. Chung TK, Cheung TH, To KF, Wong YF. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. Gynecol. Obstet. Invest. 2000 49 47 51.
8. Hellstrom AC, Blegen H, Malec M et al. Recurrent fallopian tube carcinoma: TP53 mutation and clinical course. Int. J. Gynecol. Pathol. 2000 19 145 151.
9. Rosen AC, Ausch C, Klein M et al. p53 expression in fallopian tube carcinomas. Cancer Lett. 2000 156 1 7.
10. Runnebaum IB, Kohler T, Stickeler E, Kieback HR, Kreienberg R. p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Br. J. Cancer 1996 74 1157 1160.
11. Rosen AC, Ausch C, Hafner E et al. A 15-year overview of management and prognosis in primary fallopian tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Eur. J. Cancer 1998 34 1725 1729.
12. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet. Gynecol. 2005 106 1327 1334.
13. Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006 30 230 236.
14. Heselmeyer K, Hellstrom AC, Blegen H et al. Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int. J. Gynecol. Pathol. 1998 17 245 254.
15. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat. Rev. 2006 32 180 190.
16. Stuhlinger M, Rosen AC, Dobianer K et al. HER-2 oncogene is not amplified in primary carcinoma of the fallopian tube. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Oncology 1995 52 397 399.
17. Masciullo V, Sgambato A, Pacilio C et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999 59 3790 3794.
18. Masciullo V, Ferrandina G, Pucci B et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin. Cancer Res. 2000 6 4816 4822.
19. Rosen DG, Yang G, Cai KQ et al. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin. Cancer Res. 2005 11 632 637.
20. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol. 1999 154 119 125.
21. Shigemasa K, Shiroyama Y, Sawasaki T et al. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int. J. Oncol. 2001 18 953 958.
22. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin. Cancer Res. 1999 5 2848 2853.
23. Hurteau JA, Allison BM, Brutkiewicz SA et al. Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol. Oncol. 2001 83 292 298.
24. Piek JM, Torrenga B, Hermsen B et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam. Cancer 2003 2 73 78.
25. Aziz S, Kuperstein G, Rosen B et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol. Oncol. 2001 80 341 345.
26. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001 195 451 456.
27. Snijders AM, Nowee ME, Fridlyand J et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene 2003 22 4281 4286.
28. Snijders AM, Nowak N, Segraves R et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat. Genet. 2001 29 263 264.
29. Morrison C, Zanagnolo V, Ramirez N et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J. Clin. Oncol. 2006 24 2376 2385.
30. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997 57 1199 1205.
31. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003 22 6570 6578.
32. Catzavelos C, Bhattacharya N, Ung YC et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 1997 3 227 230.
33. Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 1997 3 222 225.
34. Kim DH, Lee HI, Nam ES et al. Reduced expression of the cell-cycle inhibitor p27Kip1 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2000 36 245 251.
35. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994 78 59 66.
36. Kiyokawa H, Kineman RD, Manova-Todorova KO et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996 85 721 732.
37. Polyak K, Kato JY, Solomon MJ et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 8 9 22.
38. St Croix B, Florenes VA, Rak JW et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 1996 2 1204 1210.
39. Fang F, Orend G, Watanabe N, Hunter T, Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 1996 271 499 502.
40. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, Assoian RK. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 1996 133 391 403.
41. Yang HY, Zhou BP, Hung MC, Lee MH. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem. 2000 275 24735 24739.
42. Newman L, Xia W, Yang HY et al. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol. Carcinog. 2001 30 169 175.
43. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999 18 731 738.
44. Marches R, Uhr JW. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int. J. Cancer 2004 112 492 501.
45. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999 398 160 165.
46. Sui L, Dong Y, Ohno M et al. Jab1 expression is associated with inverse expression of p27 (kip1) and poor prognosis in epithelial ovarian tumors. Clin. Cancer Res. 2001 7 4130 4135.
47. Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J. Soc. Gynecol. Investig. 1996 3 99 105.
48. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995 269 682 685.
49. Bell DA. Origins and molecular pathology of ovarian cancer. Mod. Pathol. 2005 18 (Suppl. 2 S19 S32.
50. Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004 164 1511 1518.
51. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007 211 26 35.
52. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007 31 161 169.
53. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000 19 6115 6121.